Introducing Hypercolour: World's First Retinal Imaging Device

Focused ultrasound therapy backed by Li Ka-shing has reached a major milestone with over 1 million patients worldwide. This non-invasive technology is now being used or studied for more than 200 diseases, from cancer to neurological disorders, and is creating billion-dollar medical start-ups while expanding access to advanced care globally. Click on this link to read complete article ↓ https://lnkd.in/eU-F4rPG

September marks Prostate Health Awareness Month, and as healthcare professionals, we recognize the vital importance of early detection in improving patient outcomes. With 1 in 8 men facing a prostate cancer diagnosis in their lifetime, the role of diagnostic imaging has never been more crucial. Modern imaging technologies have transformed our ability to detect, stage, and monitor prostate-related conditions, enabling more precise treatment planning and better patient outcomes. At Consulting Radiologists, Ltd., our body imaging specialists understand the complexities involved in prostate health evaluation and provide subspecialty expertise to support healthcare teams when advanced imaging is needed. This Prostate Health Awareness Month, we encourage healthcare professionals to continue emphasizing the importance of regular screenings and appropriate imaging when indicated. Together, we can improve early detection rates and ultimately save lives. #ProstateHealthAwareness #Radiology #CRLQualityCare

🎉 JUST PUBLISHED! A game-changing systematic review on emerging cardiac CT biomarkers—cardiology/imaging fans, this is BIG! 🆕 📝 Title: Emerging cardiac CT biomarkers: a systematic review of diagnostic and prognostic utility in cardiovascular disease 👩⚕️👨⚕️ Authors: Mubariz Ahmed Hassan et al. Cardiac CT isn’t just anatomy anymore—it now quantifies functional, inflammatory & tissue biomarkers! 🫀 This review synthesized 29 human studies (2015–2025) on LAP, FAI/PCAT, FFR-CT & more! Key finds: ✅ LAP >4% predicts MI (HR 4.65!) ✅ High FAI = ~2x higher cardiac mortality ✅ FFR-CT hits 81% diagnostic accuracy vs invasive FFR These biomarkers go BEYOND stenosis severity! 🤯 Next steps? Standardize acquisition/analysis & integrate into care for personalized CVD risk stratification! 💡 👉 Read the fresh research here: https://lnkd.in/gtdvBjCq If you care about advancing CVD diagnosis—this is a MUST-READ! Let’s dive into the future of cardiac imaging together! 📚❤️ #NewCardioResearch #CardiacCT #CVDbiomarkers #MedicalImaging #HeartHealth

❓Want to know what we have been up to this past month? The September edition of our News and Research newsletter is here - featuring: 🧠 World Alzheimer’s Month ✅ Strengthening the UK’s commercial research delivery ❤️ AI stethoscope can detect 3 heart conditions in 15 seconds 🧪 Blood test that could detect ovarian cancer earlier 🚁 Drones delivering defibrillators, plus a new drug for hypertension & a tool to reduce prescribing errors 📩 Read it now: https://lnkd.in/eemXUfTJ

We're excited to announce the introduction of Molecular Microscope® Diagnostic System for Lung (MMDx® Lung), a new laboratory developed test for post-transplant biopsy assessment designed to improve the detection of lung transplant rejection and injury. Learn more about how MMDx Lung may enable more confident and accurate transplant care here: https://lnkd.in/guwgsZtp

🚨 Landmark Study Alert 🚨 Just published in J Crohn’s & Colitis — spatial transcriptomics reveals that post-operative Crohn’s disease inflammation shares a common molecular signature across colon, ileum, and the anastomosis. 👉 Key takeaway: anastomotic ulcers = inflamed ulcers, not just hypoxic ulcers. This challenges long-held assumptions and may change how we manage post-operative CD going forward. 📌 Definitely a bookmark study of 2025 for IBD clinicians and researchers. https://lnkd.in/gXpdU7sH

How are clinical experts addressing the toughest challenges in modern laboratory medicine: from AMR and sepsis diagnostics to embracing AI? Through CLINICAL24 this year, we’re bringing together clinical ambassadors and thought leaders from around the world to share practical insights and real-world solutions you can apply in your lab. The topics we’re covering include: ◾ AMR and sepsis diagnostics ◾ Cancer and personalized medicine ◾ Clinical mass spectrometry ◾ AI in the modern laboratory Visit our #CLINICAL24 hub to explore exclusive interviews and helpful tips: https://lnkd.in/eViHakWN #CLINICAL24 #ClinicalLaboratory #LabProfessionals #ClinicalResearch

Life in the lab is not without it's challenges. How we meet those challenges though, that is key to successful delivery of the service. #CLINICAL24 has brought together key opinion leaders, experts in the industry and the SelectScience Clinical audience, to discuss these challenges. And crucially, together we are exploring how technology can help us to over come them. What impact will AI, clinical mass spectrometry, rapid AST, next generation sequencing and more have on our ability to test and diagnose patients over the next few years? How can we address the challenges around implementing new technologies in the clinical lab? Visit the feature today to find out! https://lnkd.in/eViHakWN #MassSpectrometry #Healthcare #MedicalLaboratory #Sepsis #NextGenerationSequencing

#transcript Dr. Peter Altman, President and CEO of BioCardia, is focused on treating ischemic heart failure and chronic myocardial ischemia using autologous cells from the patient's bone marrow.  The company has developed a cost-effective model that utilizes a pre-procedure diagnostic to select the optimal patients for this point-of-care system, which processes their cells in a single procedure. A key technology is the Helix catheter system, which enables minimally invasive delivery of cells into the heart, aided by the Heart3D Fusion imaging platform that provides a 3D map for precise cell delivery. https://lnkd.in/gpGYTzye

The latest results from GRAIL offer vast improvements compared to their previous data, but how accurate is accurate enough to drive true clinical benefit? If 40% of positives with their multicancer early detection test don’t lead to a cancer diagnosis, is this putting more pressure on health services and inducing needless anxiety for patients? This is the complex reality for liquid biopsy tests: promising on paper, but not yet delivering what we need them to, at least not for low-risk individuals. Whether cell free DNA is the key to catching early disease is still up for debate, but as we move into this era of multiomics and AI, I will be watching the liquid biopsy field and its developments with great interest. The road to clinical implementation of liquid biopsies is not straightforward. However, their potential for diagnostics, patient stratification and disease or treatment monitoring holds strong. I found writing the latest edition of our Liquid Biopsy Playbook extremely insightful and learnt a great deal from our fantastic contributors who kindly shared their expertise. Your work is hugely inspiring and is driving this exciting field forward. I would like to extend my gratitude to the following: Catherine Alix-Panabières, Lauren C. Leiman, Jonathan Baden, Thorsten Gutjahr, Dan Stetson, Sam Wilding, Victoria Goss, Diane Mahoney, Aditi Kanhere, Shervin Tabrizi, Fabrice Lucien, Ph.D, Florent Mouliere, Alicia-Marie Conway, Dominic G. Rothwell, Dineika Chandrananda, Dimitrios Vavoulis and Anna Schuh You can read this newest edition of the Liquid Biopsy Playbook for free now! I hope you find it a useful resource, and I look forward to writing the next one. Link in the comments. #liquidbiopsy #clinicaltrial #multiomics